Quantcast
Last updated on April 17, 2014 at 7:47 EDT

Latest Blood glucose monitoring Stories

2013-05-21 08:28:43

PHILADELPHIA, May 21, 2013 /PRNewswire/ -- Echo Therapeutics, Inc. (Nasdaq: ECTE), a company developing its needle-free Symphony(®) CGM System as a non-invasive, wireless, transdermal continuous glucose monitoring system, announced today that the Company's clinical trial of its Symphony CGM System has received Institutional Review Board (IRB) approval. The IRB approval enables the commencement of a clinical evaluation of Symphony that will support the Company's CE Mark Technical File....

2013-05-16 08:27:30

Demonstration coincides with Symphony's upcoming CE Mark pivotal trial PHILADELPHIA, May 16, 2013 /PRNewswire/ -- Echo Therapeutics, Inc. (Nasdaq: ECTE), a company developing its needle-free Symphony(®) CGM System as a non-invasive, wireless, transdermal continuous glucose monitoring system, today announced the unveiling and demonstration of its Symphony CGM System to be used in its regulatory trials. The demonstration will take place during a live webcast following the annual...

2013-05-10 08:24:14

THE WOODLANDS, Texas, May 10, 2013 /PRNewswire/ -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) announced today that it is progressing into the placebo-controlled portion of its Phase 2 clinical trial of LX4211 in patients with type 1 diabetes, having successfully completed the open-label, pioneer portion of the trial. LX4211 is an investigational, oral, dual inhibitor of sodium glucose transporters 1 and 2 (SGLT1 and SGLT2). The pioneer phase of the study was designed to gain important...

2013-05-07 12:30:49

Diabetes testing supply company demonstrates quality assurance through comparative research study CHARLOTTE, N.C., May 7, 2013 /PRNewswire/ -- Prodigy Diabetes Care (Prodigy) announced today that a recent study conducted by the Duke University revealed that the Prodigy AutoCode(®) blood glucose meter and test strip system is better than, or equivalent to, the leading brands in accuracy and reliability. The comparative clinical study examined the accuracy and reliability of...

2013-05-05 23:02:13

RnRMarketResearch.com adds Latest Report on “Self Organizing Networks (SON) Challenges and Market Opportunities for LTE and beyond, Third Edition” to its store. Dallas, TX (PRWEB) May 05, 2013 Patient monitoring systems with advanced features, especially wireless or remote capability, are among the fastest-growing medical devices. The aging population and the associated increases in diseases such as congestive heart disease and diabetes as well as the cost of treating those...

2013-04-15 08:27:58

At rare, extremely high blood glucose levels (1024 mg/dL and above), the FreeStyle InsuLinx Blood Glucose Meter may provide an inaccurate reading ABBOTT PARK, Ill., April 15, 2013 /PRNewswire/ -- Abbott (NYSE: ABT) today announced it is initiating a voluntary recall of FreeStyle InsuLinx(®) Blood Glucose Meters in the United States. The company has determined that at extremely high blood glucose levels of 1024 mg/dL and above, the FreeStyle InsuLinx Meter will display and...

2013-04-10 08:30:28

DUBLIN, April 10, 2013 /PRNewswire/ -- Research and Markets ( http://www.researchandmarkets.com/research/3wm73v/global_blood) has announced the addition of the "Global Blood Glucose Test Strips Market 2011-2015" [http://www.researchandmarkets.com/research/3wm73v/global_blood ] report to their offering. (Logo: http://photos.prnewswire.com/prnh/20130307/600769 ) TechNavio's analysts forecast the Global Blood Glucose Test Strips market to grow at a CAGR of 4.57...

2013-03-21 04:20:50

Industry Thought-Leaders Highlight Paradigm-Shifting Potential of Automated, Bedside Glucose Monitoring System for Critically Ill Patients BRUSSELS, Belgium, March 21, 2013 /PRNewswire/ -- OptiScan Biomedical Corporation, a developer of innovative continuous glucose monitoring systems for use in intensive care units (ICU), today announced that the OptiScanner((TM)), the company's first-of-its-kind automated, bedside glucose monitoring system, was the focus of a special symposium at...

2013-03-18 08:28:44

PHILADELPHIA, March 18, 2013 /PRNewswire/ -- Echo Therapeutics, Inc. (Nasdaq: ECTE), a company developing its needle-free Symphony(®) CGM System as a non-invasive, wireless, transdermal continuous glucose monitoring system, today announced financial results for the year ended December 31, 2012. Echo's Annual Report on Form 10-K, as filed with the SEC, will be available by visiting the Investors section of Echo's website at www.echotx.com. (Logo:...

2013-03-15 08:26:32

PHILADELPHIA, March 15, 2013 /PRNewswire/ -- Echo Therapeutics, Inc. (Nasdaq: ECTE), a company developing its needle-free Symphony(®) CGM System as a non-invasive, wireless, transdermal continuous glucose monitoring system, today announced that it has been granted International Standards Organization (ISO) 13485:2003 certification of its quality management system, an internationally recognized quality standard for medical devices. (Logo:...